Cross talk among cells promoting anterior chamber-associated immune deviation

Chemical Immunology and Allergy

Volumn 92, Issue , 2007, Pages 115-130

  Stein Streilein, Joan ^a   Watte, Christine ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CELL SURFACE PROTEIN; DIFFERENTIATION ANTIGEN; LECTIN; LY 49 ANTIGEN; LY ANTIGEN; LY-49 ANTIGEN; MONOCYTE MACROPHAGE DIFFERENTIATION ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; UNCLASSIFIED DRUG;

ANTERIOR EYE CHAMBER; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELL COMMUNICATION; CELL INTERACTION; CELL SURFACE; CORNEA ENDOTHELIUM; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; MOLECULAR INTERACTION; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETINA; RETINA INJURY; RETINITIS; SPLEEN; SYNAPSE; T LYMPHOCYTE; TISSUE REGENERATION; ANIMAL; IMMUNOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTERIOR CHAMBER; ANTIGEN-PRESENTING CELLS; ANTIGENS, DIFFERENTIATION; ANTIGENS, LY; CELL COMMUNICATION; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; LECTINS, C-TYPE; SPLEEN;

EID: 33947520434     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000099262     Document Type: Article

References (80)

1. Streilein JW: OculaT immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3:878-889.
2. Matsubara M, Tanishima T: Wound-healing of corneal endothelium in monkey: An autoradiographic study. Jpn J Ophthalmol 1983;27:444-450.
3. Streilein JW: Regional immunity and ocular immune privilege; in Streilein JW (ed): Immune Response and the Eye. Chem Immunol. Basel, Karger, 1999, vol 73, pp 11-38.
4. Niederkorn J, Streilein JW, Shadduck JA: Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci 1980;20:355-363.
5. Jiang LQ, Jorquera M, Streilein JW: Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci 1993;34:3347-3354.
6. Wenkel H, Chen PW, Ksander BR, Streilein JW: Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space. Invest Ophthalmol Vis Sci 1999;40:3203-3208.
7. Medawar PB: Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue and to the anterior chamber of the eye. Br J Exp Pathol 1948;29:58-69.
8. Morelli AE,RThomson AW: Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 2003;196:125-146.
9. Banchereau J, Briere F, Caux C, Savoust J, Lebecque S, Lie YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:761-811.
10. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
11. Matzinger P: An innate sense of danger (review). Semin Immunol 1996;10:399-415.
12. Zhang-Hoover J, Finn P, Stein-Streilein J: Modulation of ovalbumin-induced airway inflammation and hyperreactivity by tolerogenic APC. J Immunol 2005;175:7117-7124.
13. Faunce DE, Sonoda KH, Stein-Streilein J: MIP-2 recruits NKT cells to the spleen during tolerance induction. J Immunol 2001;166:313-321.
14. Streilein JW, Stein-Streilein J, Head J: Regional specialization in antigen presentation; in: The Reticuloendothelial System. New York, Plenum, 1986, pp 37-93.
15. Taylor AW, Yee DG, Streilein JW: Suppression of nitric oxide generated by inflammatory macrophages by calcitonin gene-related peptide in aqueous humor. Invest Ophthalmol Vis Sci 1998;39:1372-1378.
16. Apte RS, Niederkorn JY: Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol 1996;156:2667-2673.
17. Streilein JW, Stein-Streilein J: Does innate immune privilege exist? J Leukoc Biol 2000;67:479-487.
18. Cousins SW, McCabe MM, Danielpour D, Streilein JW: Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 1991;32:2201-2211.
19. Streilein JW, Bradley D: Analysis of immunosuppressive properties of iris and ciliary body cells and their secretory products. Invest Ophthalmol Vis Sci 1991;32:2700-2710.
20. Hara Y, Caspi RR, Wiggert B, Dorf M, Streilein JW: Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye. J Immunol 1992;149:1531-1538.
21. Wilbanks GA, Streilein JW: Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming growth factor-beta. Eur J Immunol 1992;22:1031-1036.
22. Ohta K, Wiggert B, Yamagami S, Taylor AW, Streilein JW: Analysis of immunomodulatory activities of aqueous humor from eyes of mice with experimental autoimmune uveitis. J Immunol 2000;164:1185-1192.
23. Ohta K, Yamagami S, Taylor AW, Streilein JW: IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2000;41:2591-2599.
24. Mo JS, Streilein JW: Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. Eur J Immunol 2001;31:3806-3815.
25. Camelo S, Shanley A, Voon AS, McMenamin PG: The distribution of antigen in lymphoid tissues following its injection into the anterior chamber of the rat eye. J Immunol 2004;172: 5388-5395.
26. Streilein JW, Niederkorn JY: Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J Exp Med 1981;153:1058-1067.
27. Dullforce PA, Garman KL, Seitz GW, Fleischmann RJ, Crespo SM, Planck SR, Parker DC, Rosenbaum JT: APCs in the anterior uveal tract do not migrate to draining lymph nodes. J Immunol 2004;172:6701-6708.
28. Franklin RM, Remus LE: ConjunctivalEassociated lymphoid tissue: evidence for a role in the secretory immune system. Invest Ophthalmol Vis Sci 1984;25:181-187.
29. Zierhut M, Elson CO, Forrester JV, Kijlstra A, Kraehenbuhl JP, Sullivan DA: Mucosal immunology and the eye. Immunol Today 1998;19:148-150.
30. Hamrah P, Huq SO, Liu Y, Zhang Q, Dana MR: Corneal immunity is mediated by heterogeneous population of antigen-presenting cells. J Leukoc Biol 2003;74:172-178.
31. Cursiefen C, Schlotzer-Schrehardt U, Kuchle M, Sorokin L, Breiteneder-Geleff S, Alitalo K, Jackson D: Lymphatic vessels in vascularized human corneas: Immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci 2002;43:2127-2135.
32. Wilbanks GA, Streilein JW: The differing patterns of antigen release and local retention following anterior chamber and intravenous inoculation of soluble antigen. Evidence that the eye acts as an antigen depot. Reg Immunol 1989;2:390-398.
33. Streilein JW, Wilbanks GA: Evidence that anterior chamber and intravenous antigen injections have distinctly different systemic immune consequences. Ocular Immunol Today 1990, pp 255-258.
34. Sonoda KH, Taniguchi M, Stein-Streilein J: Long-term survival of corneal allografts is dependent on intact CD1d-reactive NKT cells. J Immunol 2002;168:2028-2034.
35. Wilbanks GA, Mammolenti M, Streilein J: Studies on the induction of anterior chamber-associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood-borne signals that induce ACAID. J Immunol 1991;146:3018-3024.
36. Wilbanks GA, Streilein JW: Studies on the induction of anterior chamber-associated immune deviation (ACAID). I. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J Immunol 1991;146:2610-2617.
37. Flugel C, Kinne RW, Streilein JW, Lutjen-Drecoll E: Distinctive distribution of HLA class II presenting and bone marrow derived cells in the anterior segment of human eyes. Curr Eye Res 1992;11:1173-1183.
38. D'Orazio TJ, Niederkorn JY: A novel role for TGb and IL-10 in the induction of immune privilege. J Immunol 1996;160:2089-2098.
39. Streilein JW: OculaT immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 2003;74:179-185.
40. + T cells to the spleen during the generation of regulatory T cells in tolerance. J Immunol 2002;169:31-38.
41. Sonoda KH, Exley M, Snapper S, Balk S, Stein-Streilein J: CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med 1999;190:1215-1225.
42. Hara Y, Okamoto S, Rouse B, Streilein JW: Evidence that peritoneal exudate cells cultured with eye-derived fluids are the proximate antigen-presenting cells in immune deviation of the ocular type. J Immunol 1993;151:5162-5171.
43. Kuchroo VK, Minami M, Diamond B, Dorf ME: Functional analysis of cloned macrophage hybridomas. VI. Differential ability to induce immunity or suppression. J Immunol 1988;141: 10-16.
44. Masli S, Turpie B, Hecker KH, Streilein JW: Expression of thrombospondin in TGFβ-treated APCs and its relevance to their immune deviation-promoting properties. J Immunol 2002;168: 2264-2273.
45. Stein-Streilein J, Streilein JW: Anterior chamber associated immune deviation (ACAID); regulation, biological relevance, and implications for therapy. Int Rev Immunol 2002;21:123-152.
46. Niederkorn JY, Mayhew E: Role of splenic B cells in the immune privilege of the anterior chamber of the eye. Eur J Immunol 1995;25:2783-2787.
47. D'Orazio TJ, Niederkorn JY: Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID). Immunology 1998;95: 47-55.
48. - T cells in mice and humans. J Exp Med 1994;180:1097-1106.
49. + T cells. Curr Opin Immunol 1995;7:367-374.
50. + T cells. J Exp Med 1997;186:109-120.
51. Brutkiewicz RR, Bennink JR, Yewdell JW, Bendelac A: TAP-independent, β2-microglobulin-independent surface expression of functional mouse CD11. J Exp Med 1995;182:1913-1919.
52. Joyce S, Woods AS, Yewdell JW, Bennink JR, De Silva AD, Boesteanu A, Balk SP, Cotter RJ, Brutkiewicz RR: Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science 1998;279:1541-1544.
53. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nakui M, Sekimoto M, Koda T: The interface between innate and acquired iGmunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 2000;12:987-994.
54. Gumperz JE, Miyake S, Yamamura T, Brenner MB: Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625-636.
55. + T regulatory cells following antigen inoculation in an immune privileged site. J Immunol 2003;171:1266-1271.
56. Sonoda KH, Faunce DE, Taniguchi M, Exley M, Balk S, Stein-Streilein J: NKT cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol 2001;166:42-50.
57. Sonoda KH, Stein-Streilein J: CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance. Eur J Immunol 2002;32:848-857.
58. Niederkorn JY, Chiang EY, Ungchusri T, Stroynowski I: Expression of a nonclassical MHC class Ib molecule in the eye. Transplantation 1999;68:1790-1799.
59. D'Orazio TJ, Mayhew E, Niederkorn JY: Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1. J Immunol 2001;166:26-32.
60. Niederkorn JY: Immune privilege in the anterior chamber of the eye. Crit Rev Immunol 2002;22: 13-46.
61. Austyn JM, Gordon S: F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 1981;11:805-815.
62. McKAight AJ, Gordon S: EGF-TM7: a novel subfamily of seven-transmembrane-region leukocyte cell-surface molecules. Immunol Today 1996;17:283-287.
63. McKnight AJ, GUrdon S: The EGF-TM7 family: unusual structures at the leukocyte surface. J Leukoc Biol 1998;63:271-280.
64. Hamann J, Vogel B, van Schijndel GM, van Lier RA: The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 1996;184:1185-1189.
65. Gordon S, Lawson L, Rabinowitz S, Crocker PR, Morris L, Perry VH: Antigen markers of macrophage differentiation in murine tissues. Curr Top Microbiol Immunol 1992;181:1-37.
66. Ezekowitz RAB, Austyn JM, Stahl PD, Gordon S: Surface properties of BCG-activated mouse macrophages. Reduced expression of mannose-specific endocytosis, Fc receptors, and antigen F4/80 accompanies induction of Ia. J Exp Med 1981;154:60-76.
67. Ezekowitz RA, Gordon S: Down-regulation of mannosyl receptor-mediated endocytosis and antigen F4/80 in bacillus Calmette-Guérin-activated mouse macrophages. Role of T lymphocytes and lymphokines. J Exp Med 1982;155:1623-1637.
68. Lin HH, Faunce DE, Stacey M, Terajewicz A, Nakamura T, Zhang-Hoover J, Kerley M, Mucenski ML, Gordon S, Stein-Streilein J: The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med 2005;201:1615-1625.
69. Katagiri K, Zhang-Hoover J, Mo JS, Stein-Streilein J, Streilein JW: Using tolerance induced via the anterior chamber of the eye to inhibit Th2-dependent pulmonary pathology. J Immunol 2002;169:84-89.
70. Chen Y, Inobe J, Weiner HL: Induction of oral tolerance to myelin basic protein in CD8-depleted mice: Both CD4+ and CD8+ cells mediate active suppression. J Immunol 1995;155:910-916.
71. Makala LHC, Reyes JCS, Nishikawa Y, Tsushima Y, Xuan X, Huang X, Battsetseg B, Matsuo T, Nagasawa H: Phenotype and function of murine discrete Peyer's patch macrophage derived-dendritic cells. J Vet Med Sci 2003;65:491-499.
72. Ikarashi Y, Mikami R, Bendelac A, Terme M, Chaput N, Terada M, Tursz T, Angevin E, Lemonnier FA, Wakasugi H, Zitvogel L: Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: Critical role for B7 in CD1d-dependent NKT cell interferon gamma production. J Exp Med 2001;194:1179-1186.
73. Maeda M, Lohwasser S, Yamamura T, Takei F: Regulation of NKT cells by Ly49: Analysis of primary NKT cells and generation of NKT cell line. J Immunol 2001;167:4180-4186.
74. Skold M, Cardell S: Differential regulation of Ly49 expression on CD4+ and CD4- CD8- (double negative) NK1.1 + T cells. Eur J Immunol 2000;30:2488-2496.
75. Held W, Cado D, Raulet DH: Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection. J Exp Med 1996;184:2037-2041.
76. Ortaldo JR, Winkler-Pickett R, Mason AT, Mason LH: The Ly-49 family: regulation of cytotoxicity and cytokine production in murine CD3+ cells. J Immunol 1998;160:1158-1165.
77. Asea A, Stein-Streilein J: Signalling through NK1.1 triggers NK cells to die but induces NKT cells to produce interleukin-4. Immunology 1998;93:296-305.
78. Wenkel H, Streilein JW, Young MJ: Systemic immune deviation in the brain that does not depend on the integrity of the blood-brain barrier. J Immunol 2000;164:5125-5131.
79. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA: NKT cell mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-520.
80. Nakamura T, Terajewicz A, Stein-Streilein J: Mechanisms of peripheral tolerance following intracameral inoculation are independent of IL-13 or ST AT6. J Immunol 2005;175:2643-2646.